ISG15 protects human Tregs from interferon alpha‐induced contraction in a cell‐intrinsic fashion. Issue 12 (23rd December 2020)
- Record Type:
- Journal Article
- Title:
- ISG15 protects human Tregs from interferon alpha‐induced contraction in a cell‐intrinsic fashion. Issue 12 (23rd December 2020)
- Main Title:
- ISG15 protects human Tregs from interferon alpha‐induced contraction in a cell‐intrinsic fashion
- Authors:
- Pacella, Ilenia
Spinelli, Francesca Romana
Severa, Martina
Timperi, Eleonora
Tucci, Gloria
Zagaglioni, Marta
Ceccarelli, Fulvia
Rizzo, Fabiana
Coccia, Eliana M
Patel, Roosheel S
Martin‐Fernandez, Marta
Bogunovic, Dusan
Conti, Fabrizio
Barnaba, Vincenzo
Piconese, Silvia - Abstract:
- Abstract: Objectives: Type I interferons (IFNs) inhibit regulatory T‐cell (Treg) expansion and activation, making them beneficial in antiviral responses, but detrimental in autoimmune diseases. Herein, we investigate the role of ISG15 in human Tregs in the context of refractoriness to type I IFN stimulation. Methods: ISG15 expression and Treg dynamics were analysed in vitro and ex vivo from patients with chronic hepatitis C, with lupus and ISG15 deficiency. Results: ISG15 is expressed at high levels in human Tregs, renders them refractory to the IFN‐STAT1 signal, and protects them from IFN‐driven contraction. In vitro, Tregs from healthy controls upregulate ISG15 upon activation to higher levels than conventional CD4 T cells, and ISG15‐silenced Tregs are more susceptible to IFNα‐induced contraction. In human ISG15 deficiency, patient Tregs display an elevated IFN signature relative to Tregs from healthy control. In vivo, in patients with chronic hepatitis C, 2 days after starting pegIFN/ribavirin therapy, a stronger ISG15 inducibility correlates with a milder Treg depletion. Ex vivo, in systemic lupus erythematosus patients, higher levels of ISG15 are associated to reduced STAT1 phosphorylation in response to IFNα, and also to increased frequencies of Tregs, characterising active disease. Conclusion: Our results reveal a Treg‐intrinsic role of ISG15 in dictating their refractoriness to the IFN signal, thus preserving the Treg population under inflammatory conditions.Abstract: Objectives: Type I interferons (IFNs) inhibit regulatory T‐cell (Treg) expansion and activation, making them beneficial in antiviral responses, but detrimental in autoimmune diseases. Herein, we investigate the role of ISG15 in human Tregs in the context of refractoriness to type I IFN stimulation. Methods: ISG15 expression and Treg dynamics were analysed in vitro and ex vivo from patients with chronic hepatitis C, with lupus and ISG15 deficiency. Results: ISG15 is expressed at high levels in human Tregs, renders them refractory to the IFN‐STAT1 signal, and protects them from IFN‐driven contraction. In vitro, Tregs from healthy controls upregulate ISG15 upon activation to higher levels than conventional CD4 T cells, and ISG15‐silenced Tregs are more susceptible to IFNα‐induced contraction. In human ISG15 deficiency, patient Tregs display an elevated IFN signature relative to Tregs from healthy control. In vivo, in patients with chronic hepatitis C, 2 days after starting pegIFN/ribavirin therapy, a stronger ISG15 inducibility correlates with a milder Treg depletion. Ex vivo, in systemic lupus erythematosus patients, higher levels of ISG15 are associated to reduced STAT1 phosphorylation in response to IFNα, and also to increased frequencies of Tregs, characterising active disease. Conclusion: Our results reveal a Treg‐intrinsic role of ISG15 in dictating their refractoriness to the IFN signal, thus preserving the Treg population under inflammatory conditions. Abstract : Tregs are particularly sensitive to the detrimental effects of type I IFNs. Here, we show that an IFN‐stimulated gene, ISG15, mediates Treg refractoriness to IFN‐induced contraction in vitro . In lupus patients, high ISG15 expression sustains high Treg frequencies in active disease. In human ISG15 deficiency, Tregs show an elevated IFN signature. … (more)
- Is Part Of:
- Clinical & translational immunology. Volume 9:Issue 12(2020)
- Journal:
- Clinical & translational immunology
- Issue:
- Volume 9:Issue 12(2020)
- Issue Display:
- Volume 9, Issue 12 (2020)
- Year:
- 2020
- Volume:
- 9
- Issue:
- 12
- Issue Sort Value:
- 2020-0009-0012-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-12-23
- Subjects:
- hepatitis C -- interferon -- ISG15 -- lupus -- STAT1 -- Tregs
Immunologic diseases -- Periodicals
Immunology -- Periodicals
Clinical medicine -- Periodicals
Immune System Diseases -- therapy
Immunotherapy
Immunologic Factors -- therapeutic use
Translational Medical Research
Molecular Targeted Therapy
Clinical medicine
Immunologic diseases
Immunology
Periodicals
Periodicals
Fulltext
Internet Resources
Periodicals
616.079 - Journal URLs:
- http://www.nature.com/cti/index.html ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/2610/ ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0068 ↗
http://www.nature.com/ ↗
http://www.nature.com/cti/index.html ↗ - DOI:
- 10.1002/cti2.1221 ↗
- Languages:
- English
- ISSNs:
- 2050-0068
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22311.xml